They can live without water, withstand radiation, survive being frozen,
have been fired from a gas gun to test their panspermia potential, and are
thought to have survived the Beresheet lunar probe's crash landing on the
Moon. They are also anticipated to be one of the last forms of life on Earth
when the sun starts to dim in about five billion years.
The fact that everyone's beloved tiny creature has yet another ability up
its chubby sleeve—a ingenious chemistry specific to tardigrades—that can
stabilize medications without refrigeration—comes as no surprise. It has
enormous promise for providing those in need of life-saving care.
Anhydrobiosis, a vital survival strategy for tardigrades, has attracted the
attention of researchers at the University of Wyoming. The research team
reasoned that the capacity of the animal to enter reversible suspended
animation in the face of excessive water loss from cells could provide the
same secure dry storage for biologic drugs that would otherwise require the
chilled environment.
Since biologics, such as vaccines, antibodies, stem cells, blood, and other
blood products, are made from living things, they must be stored in a cool
environment to prevent heat from degrading and killing the protein. Human
blood-clotting (coagulation)
factor VIII (FVIII), whose therapeutic uses include managing genetic illnesses like hemophilia
A and those with severe bodily injuries and bleeding, is one that depends on
this prohibitive cold-chain infrastructure.
The researchers discovered that it could provide FVIII with akin
desiccation shields by leveraging a particular protein and sugar that the
microscopic water bear creates in anhydrobiosis, meaning the biologic could
be dehydrated and then rehydrated for use without losing its natural
properties. Additionally, their research demonstrates that the FVIII in its
treated state stayed stable for 10 weeks.
"Access to refrigerators and freezers, as well as enough electricity to run
this infrastructure, can be in short supply in underdeveloped regions,
during natural disasters, during space flight or on the battlefield," said
Thomas Boothby, associate professor of molecular biology at UW. "Our work
provides a proof of principle that we can stabilize factor VIII, and
probably many other pharmaceuticals, in a stable, dry state at room or even
elevated temperatures using proteins from tardigrades - and, therefore,
provide critical live-saving medicine to everyone, everywhere."
The researchers improved a therapy based on the cytosolic abundant heat
soluble (CAHS) proteins and the sugar trehalose using the Hypsibius
dujardini species. The CAHS D protein, in particular, safeguards enzymes
when they are dehydrated by creating gel-like strands that preserve the
animal's cell structure. The strands withdraw when hydration is restored
without putting the cells under duress.
The team was able to stabilize the FVIII by utilizing the biophysical
characteristics of CAHS D and trehalose, which opened the way for the
development of this transfer and storing method for a variety of
biologics.
This research demonstrates that dry preservation techniques can effectively
safeguard biologics, providing a practical, physically straightforward, and
financially feasible method of stabilizing life-saving medications,
according to Boothby. This will help global health initiatives in
underdeveloped or off-the-grid regions of the world, as well as foster a
safe and prosperous space economy that will depend on new technologies to
end our reliance on refrigeration for the storage of food, medicine, and
other biomolecules.
Source:
University of Wyoming